Stem Cell Protein Stops Cancer in its Tracks
March 6, 2008
By Ivanhoe Newswire
A protein found in human embryonic stem cells is showing promise in fending off the spread of deadly cancers.
Northwestern researchers say the protein, which they’ve dubbed “Lefty,” inhibits the production of another protein known as Nodal, found in embryonic stem cells and cancer cells alike. Under normal circumstances, Nodal plays a key role in helping embryonic stem cells turn into the different cells needed in the human body, such as tissue cells, skin cells, etc.
Cancer drug: How good is good enough?
March 4, 2008
By Stephen Smith, Boston Globe
In patients stricken with advanced breast cancer, the disease can rage like a wildfire, jumping from hot spot to hot spot, sparking pain and disability.
Late last month, federal drug regulators gave their answer when they approved a drug called Avastin for treatment of patients with advanced breast cancer. The decision proved controversial because research showed that the patients on the drug didn’t live significantly longer, even though they had more time without tumor growth than patients not on Avastin.
Study Finds Death Risk From Anemia Drugs
February 28, 2008
Widely used anemia drugs sold by Amgen and Johnson & Johnson raise the risk of death among cancer patients by about 10 percent, according to a new analysis of previous clinical trials that is to be published Wednesday.
The study is the first compilation of clinical trial data — called a meta-analysis — to show a statistically significant increase in the risk of death from the drugs, said Dr. Charles L. Bennett, a professor at Northwestern University and its lead author.
New Anti-cancer Agent Can Overcome Drug Resistance, Says Study
February 26, 2008
By Science Daily
A new anti-cancer agent that targets breast cancer can overcome resistance to cancer drugs, according to a new study by the Imperial College London.
Many tumours that are initially responsive to chemotherapy can develop resistance to it, allowing the cancer to progress. Studies have shown that one of the key reasons for the development of resistance is a protein pump called P-glycoprotein. Resistant cancer cells express P-glycoprotein and this removes anti-cancer drugs from the cell before they are able to kill the cell.
The new study shows that P-glycoprotein is not able to remove a recently identified anti-cancer agent known as STX140 from cancer cells. STX140 works by stimulating a natural cell suicide process and is able to kill cancer cells which express the P-glycoprotein pump.
Avastin OK’d for breast cancer
February 23, 2008
By Daniel Costello, LA Times
FDA approves the drug’s use despite a lack of evidence that it extends patients’ lives.
In a surprise decision that could portend significant changes in how federal regulators approve cancer drugs, the Food and Drug Administration Friday approved the use of a $100,000-a-year drug for use by women with breast cancer although there is little evidence it helps breast cancer patients live longer.
Avastin, manufactured by South San Francisco-based biotech giant Genentech Inc., is already a blockbuster cancer drug used to treat advanced colon and lung cancer. Research shows the drug slows the progress of breast cancer tumors by more than five months but does not extend patients’ lives.
FDA Nears Ruling on Avastin for Breast Cancer
February 21, 2008
By Wall Street Journal
FDA is close to ruling on Avastin for Breast Cancer.
Genentech Inc.’s push to market Avastin for breast cancer has split the cancer community, which remains divided despite an 11th-hour boost last week from news of a study involving the drug by Genentech’s majority shareholder, Roche Holding AG.
The FDA is due to decide on Avastin by Saturday, but the outcome is far from assured. Members of an agency advisory committee voted 5-4 against approval in December. While the FDA isn’t required to follow the panel’s recommendations, it usually does. European regulatory authorities approved Avastin for breast cancer last March.
New Phase 2b Clinical Trial for MBC Patients treated with Avastin(R)
February 16, 2008
Accelerated Community Oncology Research Network, Inc. (ACORN), announced the initiation of a Phase 2b clinical trial evaluating the efficacy of Nexavar(R) (sorafenib) tablets in combination with the anticancer drug gemcitabine (Gemzar(R)) in patients with metastatic breast cancer whose cancer has progressed during or after treatment with bevacizumab (Avastin(R)).
The double-blind, randomized trial will enroll a total of 220 patients at approximately 45 sites in approximately 20 states and will assess efficacy, safety and patient quality of life as endpoints. Patients will be randomly assigned to receive either Nexavar and gemcitabine, or placebo and gemcitabine.
Genentech’s Avastin does well in breast cancer test
February 14, 2008
By SanFrancisco Business Times
Genentech Inc. said Tuesday that its drug Avastin did well in a Phase III trial in combination with another treatment against breast cancer.
Neuroscientists Offer Hope For Breast Cancer Patients Suffering From ‘Chemobrain’
February 9, 2008
Mental function in cancer patients with “chemobrain” can be improved by training with the Posit Science (R) Brain Fitness Program. The data will be presented by researchers at the International Neuropsychological Society’s annual meeting.
Nineteen breast cancer patients, all women, who underwent chemotherapy and reported having “chemobrain” participated in the study.
Tumor-Specific Imaging for Breast Cancer at Thomas Jefferson University
February 7, 2008
By PR Newswire
PARK CITY, Utah -- NuView Radiopharmaceuticals, Inc. (NuView) has executed an agreement with Thomas Jefferson University (Jefferson) for the exclusive distribution and commercialization rights for a tumor-specific imaging agent that assists in the diagnosis of breast and prostate tumors. NuView also intends to sponsor research at Jefferson to further develop the technology.